ResMed Inc. vs Utilities Select Sector SPDR Fund — how do they compare? ResMed Inc. trades at $194.34 (market cap $28.81B), while Utilities Select Sector SPDR Fund trades at $44.98. The key difference: ResMed Inc. pays a 1.21% dividend while Utilities Select Sector SPDR Fund pays none, and Utilities Select Sector SPDR Fund is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| RMD | XLU | |
|---|---|---|
Market Cap | $28.81B | — |
Sector | Health | — |
52-Week High | $293.73 | $47.73 |
52-Week Low | $182.82 | $41.31 |
Enterprise Value | $27.99B | — |
Dividend Yield | 1.21% | — |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
XLU trades at $44.93, down 0.51% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The ETF benefits from strong AI-driven power demand tailwinds, positioning utilities as growth plays amid sector rotation. Recent news highlights its role in the AI infrastructure boom, with defensive characteristics attracting investors during tech volatility.
Outlook is positive due to structural electricity demand growth from AI data centers, though regulatory risks and execution challenges remain. The ETF offers stable dividends and exposure to regulated utilities, with Wall Street sentiment leaning bullish on earnings potential. Key risks include grid capacity constraints and interest rate sensitivity.
Trailing returns across standard periods
Latest headlines on both assets
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →